The emerging therapeutic value of 5-MeO-DMT: a brief overview of naturalistic research and rising concerns related to future patient accessibility.

In my previous post, in this series centered around “Pharmaceutical inequalities”, I wrote about my experience working at an ibogaine clinic in Mexico. I shared that the seven-day program I developed there integrated individual counseling, group therapy, psychoeducation modules, relapse prevention education, art therapy practices, self-compassion journaling exercises, goal planning for after-care , and a 5-MeO-DMT therapy session; and that a future post would address the emerging use of 5-MeO-DMT as a mental health tool. In this second post, I am setting out to do just that.

Read more

CFP: Psychedelic Capitalism: From Forest Retreat to Fortune 500 and Pharmacies

History of Pharmacy and Pharmaceuticals, the official journal of the American Institute of the History of Pharmacy (AIHP), is pleased to announce a call for papers for a special issue: “Psychedelic Capitalism: From Forest Retreat to Fortune 500 and Pharmacies.” The issue is anticipated to appear in 2023. Guest editors for the special issue will be Drs. Neşe Devenot and Brian Pace, both of The Ohio State University.

Read more

Sex, Vaccines, and Drug Prescriptions

Editor’s Note: This post by Ejura Salihu is the third in our Pharmaceutical Inequalities series. Ejura’s experience of a disrupted menstrual cycle post-COVID19 vaccination prompted her to write a much-needed commentary on why medical trials repeatedly overlook women’s needs and health. The Pharmaceutical Inequalities series is funded by the Holtz Center and the Evjue Foundation.

Read more

From King of Opium Substitutes to Global Health and Beauty Retailer: A S Watson

This article is an abstract of Patrick Chiu’s forthcoming book “Transformation from Colonial Chemist to Global Health and Beauty Retailer: A S Watson” due to release at the end of May 2022. Pre-ordering at the Amazon Books is available or World Scientific with the discount code WSASOC20, valid until September 30, 2022.

Read more

Disparities & Inequalities in Ending the HIV Epidemic: Pre-exposure Prophylaxis (PrEP)

Editor’s Note: This post by Maeleigh Tidd is the second in our Pharmaceutical Inequalities series. She explores the recent Ending the HIV Epidemic Initiative in the US, with a particular focus on prevention strategies, specifically PrEP, that are being implemented to assist in ending the epidemic. The Pharmaceutical Inequalities series is funded by the Holtz Center and the Evjue Foundation.

Read more

Psychedelics in the treatment of substance use disorders: the case of ibogaine for the treatment of opioid dependence.

Editor’s Note: This post by Anny Ortiz is the first in our Pharmaceutical Inequalities series. She explores the existing research landscape of psychedelics and then draws upon her own lived experience of working in a treatment center that offered ibogaine-assisted detoxification to discuss the affordances and unanswered questions of using psychedelics in treatment. The Pharmaceutical Inequalities series is funded by the Holtz Center and the Evjue Foundation.

Read more

Points Interview: Dr Reiko Kanazawa

Today’s post features an interview with Reiko Kanazawa, a postdoctoral fellow at the University of Edinburgh. She is a contemporary historian of global health, international development and drug control, with a particular focus on South Asian Studies.

Reiko recently authored ‘Governing Drugs Globally: The World Health Organization and Public Health in International Drug Control‘ within the Spring 2022 issue of the Social History of Alcohol and Drugs. Find out more about Reiko’s background, article and future research plans in this interview.

Read more